NEW YORK--(BUSINESS WIRE)--

The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Derma Sciences, Inc. (NASDAQ:DSCI) stock prior to January 10, 2017.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Derma Sciences to Integra LifeSciences Holdings Corporation (NASDAQ: IART). Under the terms of the transaction, Derma Sciences common shareholders will receive $7 per share, while holders of Series A Convertible Preferred Stock will receive $32 per share, and holders of Series B Convertible Preferred Stock will receive $48 per share. To learn more about the action and your rights, go to:

http://zlk.9nl.com/dermasciences-dsci

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170127005434/en/